|
128 Companies |
|
121 Products |
|
121 Products |
|
104 Mechanisms of Action |
|
7 Trials |
|
1812 News |
|
| «12...25262728293031323334353637» |
- Enrollment change: Immunopathogenesis of Food Allergy and Eosinophilic Gastrointestinal Disorders (clinicaltrials.gov) - Apr 30, 2012
P=N/A, N=400, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=300 --> 400
- ||| Trial completion: A Study of Single and Multiple Doses of Rabeprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Months Old, Inclusive (clinicaltrials.gov) - Apr 30, 2012
P1, N=51, Completed, Sponsor: Janssen Research & Development, LLC
N=300 --> 400 Recruiting --> Completed
- ||| New P2/3 trial: NewBreez Safety and Efficacy Evaluation (clinicaltrials.gov) - Apr 26, 2012
P2/3, N=20, Recruiting, Sponsor: ProTiP Medical
- Enrollment open: Transversalis Fascial Plane Nerve Block in Iliac Crest Bone Graft (clinicaltrials.gov) - Apr 24, 2012
P=N/A, N=56, Recruiting, Sponsor: University Health Network, Toronto
Recruiting --> Completed Not yet recruiting --> Recruiting
- propranolol / Generic mfg.
Trial termination: Banding Versus Propranolol for Primary Prophylaxis of Variceal Bleeding (clinicaltrials.gov) - Apr 19, 2012
P3, N=120, Terminated, Sponsor: University of Padova
Not yet recruiting --> Recruiting Recruiting --> Terminated; From the interim analysis resulted that more than 1000 patients were required to demonstrate a significant difference between the 2 treatments.
- HEOR: A Survivorship Care Plan for Gynaecological Cancer Patients (clinicaltrials.gov) - Apr 19, 2012
P=N/A, N=75, Recruiting, Sponsor: Royal Marsden NHS Foundation Trust
- Trial withdrawal: Longitudinal Study of Children With a Chronic Cough and the Impact of Gastroesophageal Reflux (clinicaltrials.gov) - Apr 18, 2012
P3, N=0, Withdrawn, Sponsor: Massachusetts Eye and Ear Infirmary
Recruiting --> Terminated; From the interim analysis resulted that more than 1000 patients were required to demonstrate a significant difference between the 2 treatments. Completed --> Withdrawn
- Dexilant (dexlansoprazole) / Takeda
Trial withdrawal: Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis (clinicaltrials.gov) - Apr 17, 2012
P1/2, N=0, Withdrawn, Sponsor: Mayo Clinic
Completed --> Withdrawn Not yet recruiting --> Withdrawn
- Dexilant (dexlansoprazole) / Takeda
Enrollment change: Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis (clinicaltrials.gov) - Apr 17, 2012
P1/2, N=0, Withdrawn, Sponsor: Mayo Clinic
Not yet recruiting --> Withdrawn N=60 --> 0
- || 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., paclitaxel / Generic mfg.
New P3 trial, Metastases: A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma (clinicaltrials.gov) - Apr 17, 2012
P3, N=436, Recruiting, Sponsor: Fudan University
- || Enrollment change: The Study to Describe Symptom Control and Impact on Daily Life in Gastroesophageal Reflux Disease (GERD) Patients (clinicaltrials.gov) - Apr 15, 2012
P=N/A, N=1233, Completed, Sponsor: AstraZeneca
N=60 --> 0 N=900 --> 1233
- | New P2 trial: Feasibility Study for Evaluating the Effect of Electrical Stimulation on Lower Esophageal Sphincter Pressure and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease (clinicaltrials.gov) - Apr 15, 2012
P2, N=24, Completed, Sponsor: EndoStim Inc.
- ||| Trial completion: The Study to Describe Symptom Control and Impact on Daily Life in Gastroesophageal Reflux Disease (GERD) Patients (clinicaltrials.gov) - Apr 15, 2012
P=N/A, N=1233, Completed, Sponsor: AstraZeneca
N=900 --> 1233 Recruiting --> Completed
- Enrollment change: Comparison of Standard of Care or Treatment on Protocol (clinicaltrials.gov) - Apr 12, 2012
P=N/A, N=13, Terminated, Sponsor: New Mexico Cancer Care Alliance
Recruiting --> Completed N=2000 --> 13
- Vectibix (panitumumab) / Amgen, Takeda
Trial termination: PANORAMIC: Radio-chemotherapy With or Without Panitumumab (Vectibix (clinicaltrials.gov) - Apr 11, 2012
P2, N=4, Terminated, Sponsor: Radboud University
N=2000 --> 13 Recruiting --> Terminated; low recruitment numbers
- Vectibix (panitumumab) / Amgen, Takeda
Enrollment change: PANORAMIC: Radio-chemotherapy With or Without Panitumumab (Vectibix (clinicaltrials.gov) - Apr 11, 2012
P2, N=4, Terminated, Sponsor: Radboud University
Recruiting --> Terminated; low recruitment numbers N=124 --> 4
- | New P1/2 trial: Impact of Weight Loss on Gastroesophageal Reflux Disease in Overweight and Obese Subjects: a Prospective Study (clinicaltrials.gov) - Apr 8, 2012
P1/2, N=100, Recruiting, Sponsor: Midwest Biomedical Research Foundation
- ||||||| Cinqair (reslizumab) / Merck (MSD), UCB, Teva
Trial completion: Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis (clinicaltrials.gov) - Apr 8, 2012
P3, N=190, Completed, Sponsor: Ception Therapeutics
N=124 --> 4 Active, not recruiting --> Completed
- HEOR: Quality of Life in Barrett's Esophagus and Gastro-Esophageal Reflux Disease (clinicaltrials.gov) - Apr 4, 2012
P=N/A, N=384, Recruiting, Sponsor: Midwest Biomedical Research Foundation
- || New P3 trial: Endoscopic Resection or Ablation for Patients With Dysplasia or Cancer Requiring Treatment of Barrett's Esophagus (clinicaltrials.gov) - Apr 4, 2012
P3, N=82, Recruiting, Sponsor: Midwest Biomedical Research Foundation
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Apr 3, 2012
P2, N=63, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial withdrawal: A New Nasopharyngeal pH Probe for Diagnosis of Laryngopharyngeal Reflux (clinicaltrials.gov) - Mar 28, 2012
P4, N=0, Withdrawn, Sponsor: Children's Hospital of Philadelphia
Active, not recruiting --> Completed Recruiting --> Withdrawn
- Enrollment change: A New Nasopharyngeal pH Probe for Diagnosis of Laryngopharyngeal Reflux (clinicaltrials.gov) - Mar 28, 2012
P4, N=0, Withdrawn, Sponsor: Children's Hospital of Philadelphia
Recruiting --> Withdrawn N=35 --> 0
- Clinical: Study of Tongue Strengthening for Swallowing Problems (clinicaltrials.gov) - Mar 26, 2012
P=N/A, N=100, Not yet recruiting, Sponsor: University of Wisconsin, Madison
- Vectibix (panitumumab) / Amgen
Trial termination: Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma (clinicaltrials.gov) - Mar 26, 2012
P2, N=1, Terminated, Sponsor: Accelerated Community Oncology Research Network
N=35 --> 0 Active, not recruiting --> Terminated; Safety concern in a similar trial enrolling the same patient population
- |||| Enrollment open: Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer (clinicaltrials.gov) - Mar 26, 2012
P1/2, N=52, Recruiting, Sponsor: Emory University
Active, not recruiting --> Terminated; Safety concern in a similar trial enrolling the same patient population Not yet recruiting --> Recruiting
- sirolimus / Generic mfg.
Enrollment open: Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (clinicaltrials.gov) - Mar 25, 2012
P1, N=30, Recruiting, Sponsor: Roswell Park Cancer Institute
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Trial completion: A Pharmacokinetics, Pharmacodynamics and Safety Study of Rabeprazole in New Born Infants With Gastroesophageal Reflux Disease (GERD) (clinicaltrials.gov) - Mar 25, 2012
P1, N=69, Completed, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Recruiting --> Completed
- Enrollment change: GIVTE: Venous Thromboembolism and Haemostatic Disturbances in Patients With Upper Gastrointestinal Cancer (clinicaltrials.gov) - Mar 22, 2012
P=N/A, N=285, Completed, Sponsor: University of Aarhus
Recruiting --> Completed N=150 --> 285
- Trial completion: GIVTE: Venous Thromboembolism and Haemostatic Disturbances in Patients With Upper Gastrointestinal Cancer (clinicaltrials.gov) - Mar 22, 2012
P=N/A, N=285, Completed, Sponsor: University of Aarhus
N=150 --> 285 Recruiting --> Completed
- Enrollment closed, Metastases: Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach (clinicaltrials.gov) - Mar 21, 2012
P2, N=61, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion: rTMS AVC: Repetitive Transcranial Stimulation (rTMS) in Post Stroke Dysphagia (clinicaltrials.gov) - Mar 21, 2012
P4, N=30, Completed, Sponsor: University Hospital, Rouen
Recruiting --> Active, not recruiting Recruiting --> Completed
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., erlotinib / Generic mfg.
New P1 trial, Surgery, Metastases: Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction (clinicaltrials.gov) - Mar 20, 2012
P1, N=64, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Combination therapy, Metastases: Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas (clinicaltrials.gov) - Mar 20, 2012
P1, N=108, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting --> Completed Active, not recruiting --> Completed
- Xolair (omalizumab) / Roche, Novartis
Enrollment change: Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease Model (clinicaltrials.gov) - Mar 12, 2012
P1, N=19, Completed, Sponsor: O & O Alpan LLC
Active, not recruiting --> Completed N=24 --> 19
- | Trial completion: Pharmacodynamic and Pharmacokinetic Study of E3710 Following Oral Administration to Healthy, Male, Japanese Subjects (clinicaltrials.gov) - Mar 12, 2012
P1, N=30, Completed, Sponsor: Eisai Co., Ltd.
N=24 --> 19 Not yet recruiting --> Completed
- | Xolair (omalizumab) / Roche, Novartis
Trial completion: Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease Model (clinicaltrials.gov) - Mar 12, 2012
P1, N=19, Completed, Sponsor: O & O Alpan LLC
Not yet recruiting --> Completed Recruiting --> Completed
- Enrollment change: BENCH: Biology in Patients With Reflux Esophagitis (clinicaltrials.gov) - Mar 11, 2012
P=N/A, N=120, Active, not recruiting, Sponsor: Vanderbilt University
Recruiting --> Completed N=50 --> 120
- Enrollment open: Validity of a New Stroke Dysphagia Screening Tool (clinicaltrials.gov) - Mar 11, 2012
P=N/A, N=18, Recruiting, Sponsor: Rhode Island Hospital
N=50 --> 120 Not yet recruiting --> Recruiting
- carboplatin / Generic mfg., capecitabine / Generic mfg., epirubicin / Generic mfg.
Trial completion, Metastases: Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor (clinicaltrials.gov) - Mar 6, 2012
P1/2, N=0, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- New P3 trial: TAMEO: Peroral Endoscopic Myotomy for Primary Esophageal Achalasia (clinicaltrials.gov) - Mar 5, 2012
P3, N=16, Recruiting, Sponsor: Hospices Civils de Lyon
- | omeprazole / Generic mfg., fluoxetine / Generic mfg.
Trial completion: Comparing Omeprazole With Fluoxetine for Treatment of Non Erosive Reflux Disease and Its Subgroups: a Double-blind Placebo-controlled Clinical Trial (clinicaltrials.gov) - Mar 4, 2012
P2/3, N=144, Completed, Sponsor: Tehran University of Medical Sciences
Active, not recruiting --> Completed Recruiting --> Completed
- Enrollment change: Acceptability of Less Harmful Alternatives to Cigarettes (clinicaltrials.gov) - Mar 4, 2012
P=N/A, N=67, Completed, Sponsor: Roswell Park Cancer Institute
Recruiting --> Completed N=100 --> 67
- Trial completion: Acceptability of Less Harmful Alternatives to Cigarettes (clinicaltrials.gov) - Mar 4, 2012
P=N/A, N=67, Completed, Sponsor: Roswell Park Cancer Institute
N=100 --> 67 Active, not recruiting --> Completed
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg.
Trial completion, Surgery: S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction (clinicaltrials.gov) - Mar 4, 2012
P2, N=98, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || cisplatin / Generic mfg., docetaxel / Generic mfg.
New P3 trial: Involved Field Irradiation (IFI) Versus Elective Nodal Irradiation (ENI) for Esophageal Cancer (clinicaltrials.gov) - Mar 3, 2012
P3, N=320, Active, not recruiting, Sponsor: LANG Jin-yi
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, Aqupla (nedaplatin) / Simcere
Trial completion, Metastases: S-1 Plus Nedaplatin With Concurrent Radiotherapy for Advanced Esophageal Cancer (clinicaltrials.gov) - Mar 3, 2012
P1, N=15, Completed, Sponsor: Zhejiang Cancer Hospital
Active, not recruiting --> Completed Recruiting --> Completed
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Trial completion: S-1 and Radiotherapy in Elderly Patients With Esophageal Cancer (clinicaltrials.gov) - Mar 3, 2012
P1, N=12, Completed, Sponsor: Zhejiang Cancer Hospital
Recruiting --> Completed Recruiting --> Completed
- |||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
Trial completion, Metastases: Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Feb 29, 2012
P2, N=135, Completed, Sponsor: PharmaEngine
Recruiting --> Completed Active, not recruiting --> Completed
- Trial initiation date: Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer (clinicaltrials.gov) - Feb 28, 2012
P2, N=150, Active, not recruiting, Sponsor: Radiation Therapy Oncology Group
Active, not recruiting --> Completed Initiation date: Jan 2011 --> Feb 2012